CN113812630A - Composition for improving osteoporosis and preparation method thereof - Google Patents
Composition for improving osteoporosis and preparation method thereof Download PDFInfo
- Publication number
- CN113812630A CN113812630A CN202111212571.8A CN202111212571A CN113812630A CN 113812630 A CN113812630 A CN 113812630A CN 202111212571 A CN202111212571 A CN 202111212571A CN 113812630 A CN113812630 A CN 113812630A
- Authority
- CN
- China
- Prior art keywords
- parts
- improving osteoporosis
- chinese medicine
- traditional chinese
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 24
- 241000208688 Eucommia Species 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 21
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 16
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 16
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 43
- 239000008187 granular material Substances 0.000 claims description 30
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims description 13
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 13
- 244000182216 Mimusops elengi Species 0.000 claims description 13
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 13
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- 229930189775 mogroside Natural products 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 11
- 230000003179 granulation Effects 0.000 claims description 11
- 235000010439 isomalt Nutrition 0.000 claims description 9
- 239000000905 isomalt Substances 0.000 claims description 9
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 18
- 235000013399 edible fruits Nutrition 0.000 abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- 244000241838 Lycium barbarum Species 0.000 abstract description 3
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 3
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 20
- 230000037182 bone density Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 241001116742 Drynaria Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010068975 Bone atrophy Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 244000237330 gutta percha tree Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition for improving osteoporosis, which comprises the following components, by mass, 4-7.5 parts of rhizoma drynariae, 4-6.25 parts of salted eucommia bark, 2-3 parts of rhizoma polygonati, 2-3.75 parts of wolfberry fruit, 1-2 parts of Chinese date and 0.2-0.25 part of pearl powder. The dosage of the composition rhizoma drynariae and salted eucommia bark adopted by the invention is greatly reduced, and the composition is warm but not dry. The rhizoma drynariae and the salted eucommia are adopted to be compatible with the rhizoma polygonati, the prescription has obvious effects of increasing bone mineral density and improving osteoporosis, and the compatibility mode has a synergistic effect.
Description
Technical Field
The invention relates to the field of health-care food, in particular to a traditional Chinese medicine composition for improving osteoporosis and a preparation method thereof.
Background
Osteoporosis is the most common bone disease, and is a systemic bone disease characterized by low bone mass, damaged microstructure of bone tissue, increased bone fragility, and susceptibility to fracture. With the aging of population becoming more and more serious, osteoporosis becomes an important public health problem in China. The prevalence rate of osteoporosis of people over 50 years old in China is 20.7 percent for female and 14.4 percent for male; the prevalence rate of osteoporosis of people over 60 years old is obviously increased, and women are particularly prominent. Osteoporotic fractures are extremely harmful, requiring a large investment in human, material and financial resources, creating a heavy burden on the family and society. According to prediction in 2015, the medical expenses for major osteoporotic fractures (wrist, vertebral body and hip) in 2015, 2035 and 2050 in China are respectively as high as 720 billion yuan, 1320 billion yuan and 1630 billion yuan.
Traditional Chinese medicine belongs to osteoporosis in the category of 'bone atrophy'. The kidney deficiency is the main pathogenesis of osteoporosis. The traditional Chinese medicine holds that the kidney stores essence, the essence generates marrow, and the marrow nourishes bones. Su Wen, Yin Yang Ben Bing Lun Yun (cloud): "Kidney-producing bone marrow … … is bone … … in vivo. "further elucidates the relationship between the kidney and the bone and marrow, i.e., the kidney governs the bone. Therefore, kidney essence and qi are essential factors for differentiating kidney essence and bone, and kidney essence is abundant, so bone marrow is nourished and self-nourished. If kidney essence and qi deficiency lead to failure of bone marrow, bone marrow collapse will inevitably lead to bone atrophy. Just as the theory of plain question and inverse tone, its main remarks are: the kidney is also in the bone, but not in the marrow, so it is cold and even in the bone. "especially indicates the pathogenesis of kidney deficiency, marrow discontent and bone failure.
According to the action of the drugs for treating osteoporosis, the drugs can be divided into three main categories: basic medication: calcium agent and vitamin D promote normal development of skeleton, and are essential elements for human body. ② inhibiting bone resorption: estrogens, bisphosphonates, calcitonin, selective estrogen receptor modulators, and the like. The most commonly used anti-osteoporosis drugs. ③ the medicine for promoting bone formation: fluoride, parathyroid hormone, androgen, vitamin K, and the like. The ideal curative effect can be achieved by reasonably matching the medicines, but the side effect is also large.
Modern pharmacological studies show that the rhizoma drynariae has the effect of improving osteoporosis, but the dosage of the rhizoma drynariae is large, which is converted into the dosage of 35 g crude drugs/day for adults (Xianserine, Judamong, Jinzhao Ning. the total flavonoids of the rhizoma drynariae have the influence on the bone density and the bone tissue morphology and the metrology of ovariectomized rats [ J ]. Chinese traditional medicine journal, 2004,29(4): 343-. Modern pharmacological studies show that the salt eucommia bark has the effect of improving osteoporosis, and the consumption of the salt eucommia bark is up to 58.32 g crude drugs/day (Tongyan, Lina, Lirui and the like. the influence of the salt eucommia bark on the bone density and serum IGF-I of castrated rats [ J ]. China J.J.Experimental and prescriptions, 2013,19(17): 255-257.). The drynaria rhizome and the salted eucommia bark in the medicinal and edible medicinal materials have the effect of definitely improving the osteoporosis, but the use amount is very large, so that the daily health preservation and health care are not facilitated; on the other hand, the consumption of wild resources is increased.
In addition, the drynaria rhizome and the salt eucommia bark are warm in nature, and should be used with cautions for patients with yin deficiency, fire excess, blood deficiency and wind dryness when being used singly, and adverse reactions such as constipation, dry mouth and the like are caused when the dosage is too large, so that the drynaria rhizome and the salt eucommia bark are not beneficial to long-term health care or long-term eating of patients with osteoporosis. For example, the chinese patent CN 108619314B discloses a method for preparing traditional Chinese medicine granules for increasing bone density. The traditional Chinese medicine composition comprises rhizoma drynariae, astragalus, salted eucommia, medlar, Chinese date and pearl powder, and symptoms such as constipation, excessive internal heat and the like appear in the process of applying the composition to human body trial.
Therefore, on the basis of the prior art, the dosage of rhizoma drynariae and salted eucommia bark is reduced, and the formula which is warm but not dry and plays the roles of increasing bone density and improving osteoporosis is necessary.
Disclosure of Invention
Based on the defects of the prior art, the invention aims to provide a composition for improving osteoporosis and a preparation method thereof. The composition provided by the invention can increase the bone density and the bone calcium content, improve the bone metabolism, promote the bone formation and inhibit the bone absorption, is warm and not dry, and is safe and effective.
In order to achieve the purpose, the invention adopts the technical scheme that:
the composition for improving osteoporosis comprises the following raw materials in parts by mass:
4-7.5 parts of rhizoma drynariae, 4-6.25 parts of salted eucommia bark, 2-3 parts of rhizoma polygonati, 2-3.75 parts of medlar, 1-2 parts of Chinese date and 0.2-0.25 part of pearl powder.
The auxiliary materials used for forming the preparation comprise the following raw materials in percentage by mass:
4-8 parts of isomalt, 4-8 parts of maltodextrin and 0.04-0.16 part of mogroside.
Preferably, the auxiliary materials comprise the following raw materials in percentage by mass:
4 parts of isomalt, 4 parts of maltodextrin and 0.12 part of mogroside.
The invention has the following effects:
the rhizoma Drynariae is rhizoma Drynariae and rhizoma DrynariaeDrynaria fortunei(Kunze) J.Sm. drynaria rhizome, commercially available, is derived mainly from wild resources. The bitter taste is warm in nature, enters liver and kidney channels, and has the effects of healing wound, relieving pain, tonifying kidney and strengthening bone; can be used for treating traumatic injury, sprain, fracture, lumbago due to kidney deficiency, atrophy-flaccidity of bones and muscles, tinnitus, deafness, and odontoseisis.
The salt Eucommiae cortex is eucommia ulmoides of EucommiaceaeEucommia ulmoidesOliv, the dried bark is roasted with salt, is warm in nature and sweet in taste, enters liver and kidney meridians, and has the effects of tonifying liver and kidney and strengthening tendons and bones; can be used for treating deficiency of liver and kidney, soreness of waist and knees, weakness of bones and muscles, dizziness, pregnant hemorrhage, and threatened abortion.
The rhizoma Polygonati is Polygonatum kingianum of LiliaceaePolygonatum kingianumEt Hemsl, Polygonatum sibiricum RedPolygonatum sibiricumRed or Polygonatum cyrtonema HuaPolygonatum cyrtonemaThe dried rhizome of Hua is sweet in taste and neutral in nature, and enters spleen, lung and kidney meridians. Tonify qi and yin, invigorate spleen and tonify kidney. Modern pharmacological studies show that the polygonatum polysaccharide has the effects of increasing bone mineral density and the like.
Fructus Lycii is Solanaceae plant fructus LyciiLycium barbarumL. the dry ripe fruit has sweet and mild taste and moist quality, enters liver and kidney meridians, and is a good medicine for nourishing liver and kidney, nourishing blood and replenishing essence. Modern pharmacological studies show that the lycium barbarum polysaccharide has the effects of increasing bone mineral density and the like.
The fructus Jujubae is Rhamnaceae plant fructus JujubaeZiziphus jujubaDried ripe fruits of mill, tonify middle-jiao and qi, nourish blood and tranquilize mind, and can harmonize drug property and correct flavor.
The calcium content of the pearl powder is more than 90 percent, and the pearl powder is a high-quality and very special calcium source.
In addition, the invention also provides a preparation method of the traditional Chinese medicine granules for improving osteoporosis, which comprises the following steps:
step 1) taking the rhizoma drynariae, the salted eucommia bark, the rhizoma polygonati, the medlar and the Chinese date according to the formula amount, adding 6-10 times of water, and decocting for 1-3 times, wherein each time of extraction is 1-2 h. Filtering the extractive solutions, mixing, and concentrating under reduced pressure at 60-70 deg.C to relative density of 1.05-1.10.
And 2) adding the maltodextrin with the formula amount into the concentrated solution, fully dissolving and filtering. Putting the pearl powder, the mogroside and the isomaltitol into a boiling granulator according to the formula ratio, carrying out boiling granulation at the temperature of 60-70 ℃, and carrying out granulation and subpackage on the obtained granules to obtain the granules.
Preferably, the extraction parameters of step 1) are as follows: adding 10 times of water, and decocting for 2 times, each time for 2 hr.
The invention has the advantages that:
1) drynaria rhizome, rhizoma drynariae, and the like are monarch drugs in the formula. The salt eucommia bark tonifies liver and kidney, strengthens muscles and bones, and the salt is added into kidney to strengthen the kidney-tonifying function, thereby being a ministerial drug. Rhizoma Polygonati is sweet and neutral in taste, and has effects of invigorating qi, nourishing yin, invigorating spleen, moistening lung, and invigorating kidney; wolfberry fruit, fructus Lycii, with sweet and neutral nature and flavor, moistens the liver and kidney meridians, and is a good herb for nourishing liver and kidney, nourishing blood and replenishing essence. Rhizoma polygonati and fructus lycii can tonify kidney yin, relieve dryness caused by warm tonifying of rhizoma drynariae and eucommia, and cooperate with monarch and minister drugs to tonify kidney and strengthen bone, so that the idea of 'seeking yin from yang' is taken as an auxiliary (assistant) product in the prescription. The Chinese date has the effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves, and can be used as an assistant product for harmonizing drug properties and correcting flavor. The pearl powder is added to calm the nerves and calm the convulsion, detoxify and promote tissue regeneration, moisten skin and remove freckles, and appropriately supplement calcium. The whole formula has the effects of tonifying liver and kidney, strengthening bones and muscles, warming without dryness, increasing bone mineral density and improving osteoporosis, has no toxic or side effect, and can be taken for a long time.
2) The dosage of the rhizoma drynariae and the salt eucommia bark is far lower than that of the prior art, the consumption of wild resources of the rhizoma drynariae is slowed down, and the wild resources of the rhizoma drynariae are protected to a certain extent.
3) Experiments prove that the rhizoma drynariae and the salted eucommia bark have the synergistic effect after being matched with the rhizoma polygonati.
Detailed Description
The present invention is further described in the following description of the specific embodiments, which is not intended to limit the invention, but various modifications and improvements can be made by those skilled in the art according to the basic idea of the invention, within the scope of the invention, as long as they do not depart from the basic idea of the invention.
Example 1: preparation method of traditional Chinese medicine composition for improving osteoporosis
4kg of rhizoma drynariae, 4kg of salted eucommia bark, 2kg of rhizoma polygonati, 2kg of medlar, 2kg of Chinese date and 0.2kg of pearl powder.
Putting rhizoma Drynariae, salted Eucommiae cortex, rhizoma Polygonati, fructus Lycii, and fructus Jujubae into extraction tank, decocting with 10 times of water for 2 times, each time for 2 hr. Filtering the extractive solutions, mixing, concentrating at 60-70 deg.C under reduced pressure at a ratio of 1:1.38, adding Margarita powder, and mixing for 10 min.
Example 2: preparation method of traditional Chinese medicine composition for improving osteoporosis
6kg of rhizoma drynariae, 5.5kg of salted eucommia bark, 3kg of rhizoma polygonati, 2.5kg of medlar, 1.5kg of Chinese date and 0.2kg of pearl powder.
The composition was prepared as in example 1, and the extract was concentrated under reduced pressure at 60-70 deg.C at a ratio of 1: 1.05.
Example 3: preparation method of traditional Chinese medicine composition for improving osteoporosis
7.5kg of rhizoma drynariae, 6.25kg of salted eucommia bark, 2.5kg of rhizoma polygonati, 3.75kg of medlar, 1kg of Chinese date and 0.25kg of pearl powder.
The composition was prepared in the same manner as in example 1, and the extract was concentrated under reduced pressure at 60-70 ℃ at a ratio of 1: 0.92.
Example 4: preparation of traditional Chinese medicine granules for improving osteoporosis
400g of rhizoma drynariae, 400g of salted eucommia bark, 200g of rhizoma polygonati, 200g of medlar, 200g of Chinese date, 20g of pearl powder, 240g of maltodextrin, 160g of isomaltitol and 2.8g of mogroside.
Putting rhizoma Drynariae, salted Eucommiae cortex, rhizoma Polygonati, fructus Lycii, and fructus Jujubae into extraction tank, decocting with 10 times of water for 2 times, each time for 2 hr. Filtering the extractive solutions, mixing, concentrating at 60-70 deg.C under reduced pressure to relative density of 1.05-1.10, adding maltodextrin in the formula amount into the concentrated solution, dissolving completely, and filtering. Putting the pearl powder, the mogroside and the isomaltitol into a boiling granulator according to the formula ratio, carrying out boiling granulation at the temperature of 60-70 ℃, and carrying out granulation and subpackage on the obtained granules to obtain the granules. The granulation process is smooth, the yield is 81.8%, the moisture content of the obtained granules is less than 4%, and the dissolubility of the granules is good.
Example 5: preparation of traditional Chinese medicine granules for improving osteoporosis
333.4g of rhizoma drynariae, 333.4g of salted eucommia bark, 166.7g of rhizoma polygonati, 166.7g of medlar, 166.7g of Chinese date, 16.67g of pearl powder, 160g of maltodextrin, 240g of isomalt and 4.0g of mogroside.
The preparation of the pellets was carried out as described in example 4. The granulation process is smooth, the yield is 87.1%, the moisture content of the obtained granules is less than 4%, and the dissolubility of the granules is good.
Example 6: preparation of traditional Chinese medicine granules for improving osteoporosis
333.4g of rhizoma drynariae, 333.4g of salted eucommia bark, 166.7g of rhizoma polygonati, 166.7g of medlar, 166.7g of Chinese date, 16.67g of pearl powder, 310g of maltodextrin, 150g of isomalt and 5.8g of mogroside.
The preparation of the pellets was carried out as described in example 4. The granulation process is smooth, the yield is 83.7%, the moisture content of the obtained granules is less than 4%, and the dissolubility of the granules is good.
Example 7: preparation of traditional Chinese medicine granules for improving osteoporosis
266.8g of rhizoma drynariae, 266.8g of salted eucommia bark, 133.4g of rhizoma polygonati, 133.4g of medlar, 133.4g of Chinese date, 13.34g of pearl powder, 210g of maltodextrin, 210g of isomalt and 6.3g of mogroside.
The preparation of the pellets was carried out as described in example 4. The granulation process is smooth, the yield is 87.7%, the moisture content of the obtained granules is less than 4%, and the dissolubility of the granules is good.
Example 8: preparation of traditional Chinese medicine granules for improving osteoporosis
266.8g of rhizoma drynariae, 266.8g of salted eucommia bark, 133.4g of rhizoma polygonati, 133.4g of medlar, 133.4g of Chinese date, 13.34g of pearl powder, 160g of maltodextrin, 315g of isomalt and 1.4g of mogroside, and the granules have good dissolubility.
The preparation of the pellets was carried out as described in example 4. The granulation process was smooth with a yield of 87.4% and the resulting granules had a moisture content of less than 4%.
Comparative example 1:
weighing 4kg of rhizoma drynariae, 4kg of salted eucommia bark, 2kg of medlar, 2kg of Chinese date and 0.2kg of pearl powder.
The composition was prepared as in example 1, and the extract was concentrated under reduced pressure at 60-70 deg.C at a ratio of 1: 1.67.
Comparative example 2:
380g of rhizoma drynariae, 580g of astragalus mongholicus, 450g of salted eucommia ulmoides, 560g of wolfberry fruits, 380g of Chinese dates and 9g of pearl powder are weighed according to the patent CN 108619314A. A composition was prepared according to the method of example 1, and the extract was concentrated under reduced pressure at 60-70 ℃ at a ratio of 1: 0.57.
Comparative example 3:
rhizoma Polygonati 2kg
Putting 2kg of rhizoma polygonati into an extraction tank, decocting for 2 times with 10 times of water, and extracting for 2 hours each time. Filtering the extractive solutions, mixing, and concentrating at 60-70 deg.C under reduced pressure at a ratio of 1: 1.38.
Test example 1: research on osteoporosis improving effect of the composition
1. Materials and methods
1.1 test substance: the traditional Chinese medicine composition of the embodiment 1, the embodiment 2, the embodiment 3, the comparative example 1, the comparative example 2 and the comparative example 3, the raloxifene hydrochloride tablet, the bone strengthening capsule, the calcium carbonate and the deionized water.
1.2 Experimental animals: SPF grade SD rat, female, weight 220-.
1.3 experimental feed: soybean isoflavone AIN 93-removed feed
1.4 molding method: animals are normally bred to 3 months of age and then are randomly divided into 10 false operation groups and 110 modeling groups. After the model animals are fasted overnight, 3% sodium pentobarbital is injected into the abdominal cavity for anesthesia, and the injection volume is as follows: 1.0-1.5 mL/kg body weight; preparing hair on the skin at the middle lower part of the back, sterilizing, making about 1cm longitudinal incisions on two sides below the back, opening the abdominal cavity, exposing milky strip-shaped cellulite, and finding out red ovary therein; the No. 0 suture is used for ligating the joint of the ovary and the uterus, the ovary is cut off after ligation, the uterus is gently placed back into the abdominal cavity, and the wound is sutured layer by layer and disinfected. The operation of the sham operated animals is similar to that of the model group, but only the fat near the ovary is cut off and the ovary is reserved. The animals in the sham operation group and the model group are injected with 80 ten thousand units/mL penicillin sodium injection per animal after operation, 0.1 mL is injected per animal, 1 time is injected per day, and 3 days are continued. Animals were molded in 2 batches. All animals were fed with the soy isoflavone AIN93 feed throughout the test after molding.
1.5 animal groups:
after the model building operation is finished, 100 good-recovery rats are taken from the model building group and randomly divided into a model control group, a western medicine control group, a traditional Chinese medicine control group, a calcium carbonate group, an example 1 group, an example 2 group, an example 3 group, a comparative example 1 group, a comparative example 2 group and a comparative example 3 group according to the weight, and follow-up experiments are carried out together with a pseudo-operation group.
1.6 administration and dose design:
animals of example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3 were each gavaged with the corresponding test article for 1 time/day for 90 consecutive days; the raloxifene hydrochloride tablets (produced by the Lily Suzhou pharmaceutical Co., Ltd., prepared by deionized water to a concentration of 3 mg/mL) are administered by intragastric administration in a western medicine control group by the same method; the Chinese medicinal preparation is administered by intragastric administration to bone strengthening capsule (6.25 mg/mL prepared with deionized water, produced by Beijing Qihuang Hospital Co., Ltd.), and calcium carbonate preparation is administered by intragastric administration to calcium carbonate preparation (10 mg/mL prepared with deionized water, produced by Baishi chemical Co., Ltd., Tianjin city); the sham operation group and model control group animals were gavaged with deionized water in the same manner. The recommended dosage for each sample is designed in Table 1 for an adult based on 60 kg.
1.7 bone density determination: the left femur was taken and the total bone density of the specimen was measured by dual energy X-ray absorptiometry.
1.8 bone calcium content: after the left tibia is dried and only has constant weight, the left tibia is digested by mixed acid to prepare a determination solution, and the calcium content in the determination solution is determined by using an atomic absorption spectrophotometer.
2. Test results
The results of the bone density and bone calcium content tests of each group of animals are shown in Table 2.
Note: p <0.05 compared to sham group. Compared with the model control group, P is less than 0.05. Compared with the traditional Chinese medicine control group, # P is less than 0.05. 1P <0.05 compared to the group of comparative example 1. Compared with the group of comparative example 2, 2P is less than 0.05. 3P <0.05 compared to the control group 3.
2.1 bone Density results: compared with a sham operation group, the whole bone density and the bone calcium content of the animal of the model control group are obviously reduced, which indicates that the model building of the osteoporosis model is successful. Compared with the model control group, the rats in the western medicine control group, the calcium carbonate group, the example 1, the example 2 and the example 3 group have significantly increased bone density (P < 0.05). Compared with the traditional Chinese medicine control group, the rats of the groups of example 1, example 2 and example 3 have remarkably increased bone density (P < 0.05). Compared with the groups of comparative example 1, comparative example 2 and comparative example 3, the whole bone density of the rats of the groups of example 1, example 2 and example 3 is remarkably increased (P < 0.05).
2.2 bone calcium content results: compared with the model control group, the bone calcium content of rats in the western medicine control group, the traditional Chinese medicine control group, the calcium carbonate group, the example 1, the example 2 and the example 3 is obviously increased (P < 0.05).
From the above results, the effects of examples 1, 2 and 3 are significantly better than those of the traditional Chinese medicine control group, comparative example 1, comparative example 2 and comparative example 3, and the difference is significant (P < 0.05), which shows that examples 1, 2 and 3 of the present invention have the effects of increasing bone density and bone calcium content.
Test example 2: accelerated stability test
10g of the sample was weighed, placed in an aluminum foil bag, and left at 37. + -. 2 ℃ and RH 75. + -. 5% for 3 months for accelerated stability testing. The results are shown in Table 3.
As can be seen from table 3: the particles obtained in example 7 have good stability. The process of the embodiment 7 of the invention is to directly granulate after mixing and extraction, and the process is simple, and the cost is easier to save in large-scale production.
Claims (7)
1. The composition for improving osteoporosis comprises the following components in parts by mass:
4-7.5 parts of rhizoma drynariae, 4-6.25 parts of salted eucommia bark, 2-3 parts of rhizoma polygonati, 2-3.75 parts of medlar, 1-2 parts of Chinese date and 0.2-0.25 part of pearl powder.
2. The traditional Chinese medicine granules for improving osteoporosis of claim 1, wherein the composition comprises acceptable excipients.
3. The traditional Chinese medicine granule for improving osteoporosis as claimed in claim 2, wherein the adjuvant comprises: isomalt, maltodextrin, mogroside.
4. The traditional Chinese medicine granule for improving osteoporosis as claimed in claim 3, wherein the auxiliary materials comprise, by weight: 4-8 parts of isomalt, 4-8 parts of maltodextrin and 0.04-0.16 part of mogroside.
5. The traditional Chinese medicine granule for improving osteoporosis of claim 3, wherein the auxiliary materials for forming the preparation and the mass fraction thereof are as follows: 4 parts of isomalt, 4 parts of maltodextrin and 0.12 part of mogroside.
6. The traditional Chinese medicine granules for improving osteoporosis of claims 2-5, wherein the preparation steps are as follows:
1) taking rhizoma Drynariae, salted Eucommiae cortex, rhizoma Polygonati, fructus Lycii, and fructus Jujubae according to formula ratio, adding 6-10 times of water, decocting for 1-3 times, extracting for 1-2 hr each time, filtering extractive solutions, mixing, and concentrating under reduced pressure at 60-70 deg.C to relative density of 1.05-1.10;
2) adding maltodextrin in the formula amount into the concentrated solution, fully dissolving, filtering, putting the pearl powder, the mogroside and the isomaltitol in the formula amount into a boiling granulator, carrying out boiling granulation at the temperature of 60-70 ℃, and carrying out granulation and subpackaging on the obtained granules to obtain the granules.
7. The Chinese medicinal granule for improving osteoporosis of claim 6, wherein the preparation step 1) is carried out by adding 10 times of water and decocting for 2 times, each time for 2 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111212571.8A CN113812630A (en) | 2021-10-19 | 2021-10-19 | Composition for improving osteoporosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111212571.8A CN113812630A (en) | 2021-10-19 | 2021-10-19 | Composition for improving osteoporosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113812630A true CN113812630A (en) | 2021-12-21 |
Family
ID=78920682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111212571.8A Pending CN113812630A (en) | 2021-10-19 | 2021-10-19 | Composition for improving osteoporosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113812630A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416823A (en) * | 2001-11-07 | 2003-05-14 | 武汉华中科大纳米药业有限公司 | Medicine composition for treating osteoporosis |
| CN104187632A (en) * | 2014-08-13 | 2014-12-10 | 胡安然 | Total-nutrient formulated food eaten by patients with osteoporosis |
| CN106938005A (en) * | 2017-05-03 | 2017-07-11 | 辽宁中医药大学 | A kind of Chinese medicine composition for being used to treat osteoporosis |
| CN108619314A (en) * | 2018-06-06 | 2018-10-09 | 完美（中国）有限公司 | A kind of preparation method of Chinese medicinal granule object |
-
2021
- 2021-10-19 CN CN202111212571.8A patent/CN113812630A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416823A (en) * | 2001-11-07 | 2003-05-14 | 武汉华中科大纳米药业有限公司 | Medicine composition for treating osteoporosis |
| CN104187632A (en) * | 2014-08-13 | 2014-12-10 | 胡安然 | Total-nutrient formulated food eaten by patients with osteoporosis |
| CN106938005A (en) * | 2017-05-03 | 2017-07-11 | 辽宁中医药大学 | A kind of Chinese medicine composition for being used to treat osteoporosis |
| CN108619314A (en) * | 2018-06-06 | 2018-10-09 | 完美（中国）有限公司 | A kind of preparation method of Chinese medicinal granule object |
Non-Patent Citations (1)
| Title |
|---|
| 张磊等: "黄精多糖防治绝经后骨质疏松症的分子机制", 中国组织工程研究, vol. 22, no. 04, pages 493 - 498 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105999159A (en) | Brown sugar and saussurea involucrate composition and preparation method thereof | |
| CN100396315C (en) | Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis | |
| CN103142895B (en) | Kidney nourishing mixture and preparation method thereof | |
| CN100421699C (en) | Compound Chinese medicinal preparation for treating male sterility | |
| CN113812630A (en) | Composition for improving osteoporosis and preparation method thereof | |
| CN115089661A (en) | Application of ginseng composition for assisting in regulating endocrine metabolism and resisting and preventing cancer | |
| CN104173897B (en) | Treat the Chinese medicine composition of the menopausal syndrome as caused by ovarian failure | |
| CN106361856A (en) | Anti-osteoporosis traditional Chinese medicinal composition and preparation method thereof | |
| CN113318191A (en) | A Chinese medicinal composition for treating male infertility, sexual impotence, and premature ejaculation | |
| CN113577236A (en) | Traditional Chinese medicine composition for protecting liver, protecting stomach and sobering up, preparation and preparation method thereof | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN112618425A (en) | Preparation method of multi-effect repairing, moistening and hair nourishing essence | |
| CN105456624A (en) | Traditional Chinese medicine caring composition for post-partum recovery and preparation method thereof | |
| CN114081171A (en) | Functional food composition with function of assisting in improving sleep | |
| CN104623615A (en) | Medicine for treating asthma | |
| CN110141656A (en) | A kind of Fuke Tiaojing blood-nourishing Chinese medicine composition and preparation method thereof | |
| CN103610934A (en) | Traditional Chinese medicine for treating pharyngitis | |
| CN104147229B (en) | A kind of compound Chinese medicinal preparation for the treatment of female climacteric syndrome kidney yin and yang deficiency type | |
| CN112022988B (en) | Traditional Chinese medicine composition with effect of preventing and/or treating dysmenorrhea and preparation method and application thereof | |
| CN107854662A (en) | A kind of Chinese medicine preparation for treating cirrhotic ascites and preparation method thereof | |
| CN107441313B (en) | Traditional Chinese medicine composition and medicine for treating ovarian reserve function decline and preparation method thereof | |
| CN116172206A (en) | Rose-kudzuvine root collagen peptide composition, pressed candy and preparation method thereof | |
| CN111249416A (en) | Compound traditional Chinese medicine composition and preparation method thereof | |
| CN103815344A (en) | Dahurian rose fruit blood-activating heart-nourishing hot-pot condiment and preparation method | |
| CN105981851A (en) | Radix pseudostellariae granulated tea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |